A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes

NCT07230418 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: HRS-3095 Tablet
DRUG: HRS-3095 Placebo Tablet

Sponsor

Chengdu Suncadia Medicine Co., Ltd.